Denali leases a new R&D hub; iCo dumps its entire staff;

@FierceBiotech: Top 10 mega-rounds fuel record VC pace, with a distinctly ex-U.S. biotech accent. Report | Follow @FierceBiotech

@JohnCFierce: And in case you missed it: Eleven Bio faces cash crunch as lead drug flunks another PhIII. Article | Follow @JohnCFierce

@DamianFierce: Index Ventures' official Dick Costolo announcement is a link to his tweets of screenshots from his notes app. More | Follow @DamianFierce

> Canada's iCo Therapeutics is cutting its entire staff in an effort to conserve cash, demoting its executives to consultants after failing to secure a buyout. More

> Denali Therapeutics, working off of a $217 million funding round, has leased the entire first floor of a new life sciences hub in the Bay Area. Story

> U.K. startup Centauri Therapeutics is getting off the ground with plans to develop new therapies for infectious diseases, securing £3 million ($4.3 million) in investor commitments to move forward. News

Medical Device News

@FierceMedDev: Second activist investor buys 5% stake in HeartWare, putting Valtech deal in doubt. Article | Follow @FierceMedDev

@VarunSaxena2: Interesting article in . Which lifesci hub do you think is no. 1? More (reg. req.) | Follow @VarunSaxena2

@EmilyWFierce: Shkreli, Valeant CEO set for a grilling at Congressional price-hike hearing. FiercePharma story | Follow @EmilyWFierce

> Startup raises $19M to market suture-replacing, Zip skin closure products. Report

> J&J axes 3,000 jobs in bid to save $1B and revive lagging medical devices business. Article

Pharma News

@FiercePharma: New strain of avian flu confirmed in Indiana poultry flocks. FierceAnimalHealth item | Follow @FiercePharma

@EricPFierce: FDA says this Hong Kong plant pretty much had not quality control in place. FiercePharmaManfacturing story | Follow @EricPFierce

@CarlyHFierce: ICYMI: PTO shuts down Amgen's Humira IP challenge. Article | Follow @CarlyHFierce

> Shkreli, Valeant CEO set for a grilling at Congressional price-hike hearing. Report

> Supreme Court rebuffs another J&J appeal, leaving $140M failure-to-warn judgment intact. Article

Animal Health News

> New strain of avian flu confirmed in Indiana poultry flocks. Story

> Affymetrix teams with Bio-Genesys to offer genetic testing for livestock. More

> Animal drugs, diagnostics and distribution on display at J.P. Morgan confab. Item

> EMA launches review of 'last-resort' antibiotic after scientists ID resistance gene. Report

> Dechra's growth spurt continues with $6M acquisition of Mexican manufacturer. Article

Biotech IT News

> BioMed X emerges from Merck KGaA alliance armed with bioinformatics tools. News

> NIH kicks off $313M genome sequencing drive. Report

> Illumina moves into semiconductor-based sequencing with Project Firefly. More

> Biden puts data sharing at center of drive to cure cancer. Article

> Astellas hooks up with NuMedii to continue drug repurposing deal drive. Story

Drug Delivery News

> Dental anesthesia delivered via electric current could offer needle-free alternative. Item

> Will FDA panel's second recommendation of approval for implant to treat opioid addiction be enough? More

> Takeda teams up with enGene for gastrointestinal gene delivery R&D. Report

> Catalent to earn up to $618M under antibody-drug conjugate research alliance with Roche. Story

> Pfizer invests in 4D Molecular Therapeutics, a maker of gene delivery vectors. Article

Pharma Manufacturing News

> Mylan halts production at Poland plant after inspectors uncover problems. News

> Plant-based biologics production to be offered by new CMO. Item

> FDA slams another Chinese drugmaker with a warning letter. Story

> Emcure, which has issues with FDA, buys Canadian firms. Report

> Wockhardt's new sterile injectable plant issued a Form 483 by the FDA. Article

Pharma Asia News

> Unit of Singapore's Biosensors refuses U.S. FDA inspection. Item

> Redesigned scope by Japan's Olympus cleared by FDA. More

> Japanese drugmakers shift focus as government pushes for more generics. Report

> Sanofi may get waiver from large-scale dengue vaccine trials in India. Story

> Healthcare reform in China raises tensions between hospitals, pharma companies. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.